All In Biotech

Drug Trial Radar · NCT04964479

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

A Randomized, Blind, Parallel Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Pembrolizumab Injection as a First-line Treatment on Patient With Advanced NSCLC.

Last checked: Nov 19, 2026Latest source record: Aug 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

375

Planned (sponsor's estimate)

Start

Aug 6, 2021

Primary completion

Dec 2022

Study completion Mar 2023

Sponsor

Sponsor type
Industry
First posted
Jul 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus K drug as a first-line treatment of advanced non-small cell lung cancer.A total of 375 subjects will be enrolled.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • TQB2450 injectionDrug

    1200mg injection once every 3 week

  • Anlotinib Hydrochloride CapsulesDrug

    12mg capsule once daily

  • Pembrolizumab injectionDrug

    200mg injection once every 3 week

  • PlaceboDrug

    Placebo capsule once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease progression-free survival(PFS) evaluated by Independent Review Committee (IRC)Time frame: Baseline to up to two years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Tumor Hospital of Chongqing University

    Chongqing, China · Not yet recruiting

  • Three Gorges Hospital of Chongqing University

    Chongqing, China · Not yet recruiting

  • Southern Hospital of Southern Medical University

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Not yet recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China · Not yet recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China · Not yet recruiting

  • The Fifth Central Hospital of Tianjin

    Tianjin, China · Not yet recruiting

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Affiliated Hospital of Guangdong Medical University

    Zhangjiang, Guangdong, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The Ninth Affiliated People's Hospital of Shanghai Jiao Tong University, School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • General Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.